vs

Side-by-side financial comparison of RELIANCE, INC. (RS) and Vertex Pharmaceuticals (VRTX). Click either name above to swap in a different company.

RELIANCE, INC. is the larger business by last-quarter revenue ($3.5B vs $3.2B, roughly 1.1× Vertex Pharmaceuticals). Vertex Pharmaceuticals runs the higher net margin — 37.3% vs 3.3%, a 34.0% gap on every dollar of revenue. On growth, RELIANCE, INC. posted the faster year-over-year revenue change (11.9% vs 9.5%). Vertex Pharmaceuticals produced more free cash flow last quarter ($348.6M vs $202.9M). Over the past eight quarters, Vertex Pharmaceuticals's revenue compounded faster (8.9% CAGR vs -2.0%).

Reliance, Inc. (Reliance), headquartered in Scottsdale, Arizona, is the largest metals service center operator in North America. The company provides metals processing services and distributes a line of approximately 100,000 metal products, including aluminum, brass, alloy, copper, carbon steel, stainless steel, titanium, and specialty metal products to 125,000 customers such as fabricators and manufacturers.

Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, Oxfordshire, England.

RS vs VRTX — Head-to-Head

Bigger by revenue
RS
RS
1.1× larger
RS
$3.5B
$3.2B
VRTX
Growing faster (revenue YoY)
RS
RS
+2.4% gap
RS
11.9%
9.5%
VRTX
Higher net margin
VRTX
VRTX
34.0% more per $
VRTX
37.3%
3.3%
RS
More free cash flow
VRTX
VRTX
$145.7M more FCF
VRTX
$348.6M
$202.9M
RS
Faster 2-yr revenue CAGR
VRTX
VRTX
Annualised
VRTX
8.9%
-2.0%
RS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
RS
RS
VRTX
VRTX
Revenue
$3.5B
$3.2B
Net Profit
$116.9M
$1.2B
Gross Margin
85.4%
Operating Margin
4.8%
37.8%
Net Margin
3.3%
37.3%
Revenue YoY
11.9%
9.5%
Net Profit YoY
10.3%
30.5%
EPS (diluted)
$2.23
$4.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RS
RS
VRTX
VRTX
Q4 25
$3.5B
$3.2B
Q3 25
$3.7B
$3.1B
Q2 25
$3.7B
$3.0B
Q1 25
$3.5B
$2.8B
Q4 24
$3.1B
$2.9B
Q3 24
$3.4B
$2.8B
Q2 24
$3.6B
$2.6B
Q1 24
$3.6B
$2.7B
Net Profit
RS
RS
VRTX
VRTX
Q4 25
$116.9M
$1.2B
Q3 25
$189.5M
$1.1B
Q2 25
$234.2M
$1.0B
Q1 25
$200.5M
$646.3M
Q4 24
$106.0M
$913.0M
Q3 24
$199.2M
$1.0B
Q2 24
$268.3M
$-3.6B
Q1 24
$303.8M
$1.1B
Gross Margin
RS
RS
VRTX
VRTX
Q4 25
85.4%
Q3 25
86.5%
Q2 25
86.3%
Q1 25
86.9%
Q4 24
85.5%
Q3 24
85.8%
Q2 24
85.9%
Q1 24
87.3%
Operating Margin
RS
RS
VRTX
VRTX
Q4 25
4.8%
37.8%
Q3 25
7.1%
38.6%
Q2 25
8.5%
38.8%
Q1 25
7.9%
22.7%
Q4 24
4.5%
35.2%
Q3 24
8.0%
40.3%
Q2 24
9.7%
-132.9%
Q1 24
10.8%
42.4%
Net Margin
RS
RS
VRTX
VRTX
Q4 25
3.3%
37.3%
Q3 25
5.2%
35.2%
Q2 25
6.4%
34.8%
Q1 25
5.8%
23.3%
Q4 24
3.4%
31.4%
Q3 24
5.8%
37.7%
Q2 24
7.4%
-135.8%
Q1 24
8.3%
40.9%
EPS (diluted)
RS
RS
VRTX
VRTX
Q4 25
$2.23
$4.64
Q3 25
$3.59
$4.20
Q2 25
$4.42
$3.99
Q1 25
$3.74
$2.49
Q4 24
$2.05
$3.62
Q3 24
$3.61
$4.01
Q2 24
$4.67
$-13.92
Q1 24
$5.23
$4.21

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RS
RS
VRTX
VRTX
Cash + ST InvestmentsLiquidity on hand
$216.6M
$6.6B
Total DebtLower is stronger
Stockholders' EquityBook value
$7.2B
$18.7B
Total Assets
$10.4B
$25.6B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RS
RS
VRTX
VRTX
Q4 25
$216.6M
$6.6B
Q3 25
$261.2M
$6.3B
Q2 25
$239.5M
$6.4B
Q1 25
$277.8M
$6.2B
Q4 24
$318.1M
$6.1B
Q3 24
$314.6M
$6.5B
Q2 24
$350.8M
$5.8B
Q1 24
$934.9M
$10.2B
Stockholders' Equity
RS
RS
VRTX
VRTX
Q4 25
$7.2B
$18.7B
Q3 25
$7.3B
$17.3B
Q2 25
$7.2B
$17.2B
Q1 25
$7.1B
$16.5B
Q4 24
$7.2B
$16.4B
Q3 24
$7.4B
$15.6B
Q2 24
$7.6B
$14.8B
Q1 24
$7.9B
$18.5B
Total Assets
RS
RS
VRTX
VRTX
Q4 25
$10.4B
$25.6B
Q3 25
$10.5B
$24.9B
Q2 25
$10.5B
$24.0B
Q1 25
$10.4B
$22.9B
Q4 24
$10.0B
$22.5B
Q3 24
$10.3B
$22.2B
Q2 24
$10.4B
$20.1B
Q1 24
$10.7B
$23.9B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RS
RS
VRTX
VRTX
Operating Cash FlowLast quarter
$276.1M
$498.0M
Free Cash FlowOCF − Capex
$202.9M
$348.6M
FCF MarginFCF / Revenue
5.8%
10.9%
Capex IntensityCapex / Revenue
2.1%
4.7%
Cash ConversionOCF / Net Profit
2.36×
0.42×
TTM Free Cash FlowTrailing 4 quarters
$502.5M
$3.2B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RS
RS
VRTX
VRTX
Q4 25
$276.1M
$498.0M
Q3 25
$261.8M
$1.2B
Q2 25
$229.0M
$1.1B
Q1 25
$64.5M
$818.9M
Q4 24
$473.3M
$584.6M
Q3 24
$463.9M
$1.4B
Q2 24
$366.3M
$-3.8B
Q1 24
$126.3M
$1.3B
Free Cash Flow
RS
RS
VRTX
VRTX
Q4 25
$202.9M
$348.6M
Q3 25
$180.6M
$1.1B
Q2 25
$141.4M
$927.4M
Q1 25
$-22.4M
$778.2M
Q4 24
$362.4M
$492.0M
Q3 24
$351.1M
$1.3B
Q2 24
$268.1M
$-3.8B
Q1 24
$17.6M
$1.2B
FCF Margin
RS
RS
VRTX
VRTX
Q4 25
5.8%
10.9%
Q3 25
4.9%
37.0%
Q2 25
3.9%
31.3%
Q1 25
-0.6%
28.1%
Q4 24
11.6%
16.9%
Q3 24
10.3%
47.0%
Q2 24
7.4%
-144.5%
Q1 24
0.5%
46.0%
Capex Intensity
RS
RS
VRTX
VRTX
Q4 25
2.1%
4.7%
Q3 25
2.2%
3.3%
Q2 25
2.4%
4.9%
Q1 25
2.5%
1.5%
Q4 24
3.5%
3.2%
Q3 24
3.3%
2.4%
Q2 24
2.7%
2.6%
Q1 24
3.0%
2.5%
Cash Conversion
RS
RS
VRTX
VRTX
Q4 25
2.36×
0.42×
Q3 25
1.38×
1.15×
Q2 25
0.98×
1.04×
Q1 25
0.32×
1.27×
Q4 24
4.47×
0.64×
Q3 24
2.33×
1.31×
Q2 24
1.37×
Q1 24
0.42×
1.19×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

RS
RS

Carbon Steel$1.9B55%
Aluminum$624.5M18%
Stainless Steel$467.1M13%
Alloy Steel$155.5M4%
Toll Processing$155.3M4%
Copper And Brass$93.5M3%
Other Products Or Services$80.4M2%

VRTX
VRTX

TRIKAFTAKAFTRIO$2.6B81%
ALYFTREK$380.1M12%
Manufactured Product Other$237.4M7%

Related Comparisons